Anumana announced today that it brought its diagnostic ECG-AI technology into perioperative and acute cardiac care with help from Boston Scientific.
Anumana expands AI cardiac care platform with support from Boston Scientific
Related Articles
Anumana and Pfizer partner for cardiovascular disease detection
Medical Device Network: Health technology company Anumana and Pfizer have signed a multi-year agreement to develop an artificial intelligence electrocardiogram (AI-ECG) algorithm for the early detection of cardiac amyloidosis. Under…December 16, 2022
Anumana, Inc. announced that it has received funding from Boston Scientific Corporation, Matrix Capital Management, Mayo Clinic, Endowment Arm, Matrix Management Corporation, NTT Venture Capital
MarketScreener: Anumana, Inc. announced that it has received a round of funding from new investor, Boston Scientific Corporation on April 24, 2025. The transaction included participation from returning investors, Matrix…April 24, 2025
Researchers use AI to detect weak heart pump via patients’ Apple Watch ECGs
Medical Xpress: Single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic effectively identified patients with a weak heart pump. To interpret…May 01, 2022
Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for…July 06, 2022